肝功能障碍对使用以体生理学为基础的药用动力学模型对托菲尼蒂德暴露的影响
Mona Darwish1, Obinna N Obianom2, James M Youakim3
1Acadia Pharmaceuticals Inc., 12830 El Camino Real, Suite 400, San Diego, CA, 92130, USA. mdarwish@acadia-pharm.com.
Advances in therapy
|July 4, 2024
概括
托菲尼提德是一种新的雷特综合征治疗方法,显示肝功能障碍对肝脏的影响最小. 药物动力学建模证实药物暴露没有临床显著变化,确保治疗的安全性和有效性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 临床药理学 临床药理学
背景情况:
- 托菲尼提德是第一个批准用于雷特综合征的治疗方法.
- 肝脏排泄不是托菲尼提德的主要排泄途径.
- 了解肝功能障碍对托菲尼提德药理动力学 (PK) 的影响至关重要.
研究的目的:
- 评估肝功能障碍对托菲尼提德PK的影响.
- 为了将不同程度的肝功能障碍的虚拟患者的托菲尼提德暴露与健康个体进行比较.
主要方法:
- 使用了基于生理学的药理动力学 (PK) 建模.
- 模拟虚拟患者轻度,中度和严重的肝功能障碍.
- 在12g口服剂量后估计了暴露指标 (Cmax,AUC).
主要成果:
- 预测的Trofinetide血暴露在所有肝功能障碍严重程度上保持相似.
- 观察到血度略有增加,肝功能衰竭增加.
- 这种增加归因于血红素水平的变化.
结论:
- 预计肝功能障碍不会对托菲尼提德暴露产生临床相关的影响.
- 这项研究支持了预期的Trofinetide的PK概况.
- 对于肝功能受损的患者,可能不需要调整剂量.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
37
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
37
Physiological Pharmacokinetic Models: Assumption with Protein Binding
39
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
39
Renal Failure: Dose Adjustments
79
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
79
Pharmacokinetic Models: Comparison and Selection Criterion
66
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
66
Model Approaches for Pharmacokinetic Data: Physiological Models
41
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
41
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
77
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
77


